Using Technology to Power Pharma and Clinical Genomics with Mike Klein
Genomenon CEO, Mike Klein met with Mike Maddox, host of ASK, to talk about Genomenon’s use of innovative technology to connect medical professionals with the scientific evidence they need to treat rare diseases and cancers.
Genomenon is 2020 Company of the Year in Global Clinical Genomics Interpretation
Genomenon was named the 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan today. The distinguished award highlights the superiority of Mastermind as a pioneering and first-in-class genomic database and leading research tool accelerating precision medicine. Below is the report in its entirety.
AI-Driven Literature Curation for Determining Genomic Variant Pathogenicity
Mark Kiel, Founder and Chief Science Officer of Genomenon was a featured presenter for the LabRoots Virtual Genetics & Genomics Event on May 8th and 9th, 2019. This is the transcript, slides and video from his talk, which opened the event on Thursday, May 9th.
Genomenon Honored as one of 50 Companies to Watch 2019
Mike Klein, CEO of Genomenon, as interviewed by Jeffrey Mosher, Operations Director of Michigan Business Network on Genomenon’s recent award as one of the Top 50 Companies to Watch in Michigan.
Don’t Call It a Comeback
Mark Kiel, Founder and Chief Science Officer of Genomenon, shares his comeback story at Startup Story Night 2019 at the Marble Bar in Detroit. Genomenon has come a very long way. Like any good story, we had our ups and downs, moments of excitement and fear while rapidly growing in a developing industry. Read about …
Top Cited Genomic Variants in 2017 – Highlighting EGFR p.C797S
Original version of this post was previously published on the Enlightenbio Blog on January 1, 2018 by Brigitte Ganter. Dr. Mark Kiel (CSO and co-Founder at Genomenon) and Lauren Chunn (Data Processing Analyst at Genomenon) were able to mine the Mastermind database of genomic variants and analyze the trending citations of widely covered variants in the …